Gyp L treatment significantly decreased the expression of HMGCS1 and HMGCR in HCC cells, leading to significant alterations in the cholesterol metabolism pathway within HCC cells and enhancement of anticancer immune responses. The gene discussed is HMGCS1; the disease is hepatocellular carcinoma.